Health related quality of life outcomes in cancer clinical trials
Bottomley, A., Flechtner, H., Efficace, F., Vanvoorden, V., Coens, C., Therasse, P., Velikova, G., Blazeby, J., Greimel, E.
Published in European journal of cancer (1990) (01.08.2005)
Published in European journal of cancer (1990) (01.08.2005)
Get full text
Journal Article
Methodological issues in assessing health-related quality of life of colorectal cancer patients in randomised controlled trials
Efficace, F, Bottomley, A, Vanvoorden, V, Blazeby, J.M
Published in European Journal of Cancer (01.01.2004)
Published in European Journal of Cancer (01.01.2004)
Get full text
Book Review
Journal Article
Management of skin reactions during radiotherapy: a study of nursing practice
D'HAESE, S., BATE, T., CLAES, S., BOONE, A., VANVOORDEN, V., EFFICACE, F.
Published in European journal of cancer care (01.03.2005)
Published in European journal of cancer care (01.03.2005)
Get full text
Journal Article
Bimekizumab versus Adalimumab in Plaque Psoriasis
Warren, Richard B, Blauvelt, Andrew, Bagel, Jerry, Papp, Kim A, Yamauchi, Paul, Armstrong, April, Langley, Richard G, Vanvoorden, Veerle, De Cuyper, Dirk, Cioffi, Christopher, Peterson, Luke, Cross, Nancy, Reich, Kristian
Published in The New England journal of medicine (08.07.2021)
Published in The New England journal of medicine (08.07.2021)
Get full text
Journal Article
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial
Strober, Bruce, Paul, Carle, Blauvelt, Andrew, Thaçi, Diamant, Puig, Luis, Lebwohl, Mark, White, Katy, Vanvoorden, Veerle, Deherder, Delphine, Gomez, Natalie Nunez, Eyerich, Kilian
Published in Journal of the American Academy of Dermatology (01.09.2023)
Published in Journal of the American Academy of Dermatology (01.09.2023)
Get full text
Journal Article
Bimekizumab versus secukinumab continuous maintenance of response at every visit through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial
Warren, RB, Conrad, C, Foley, P, Iversen, L, Langley, RG, Kokolakis, G, Davis, L, Vanvoorden, V, Wiegratz, S, Merola, JF
Published in Skin (Milwood, N.Y.) (16.11.2022)
Published in Skin (Milwood, N.Y.) (16.11.2022)
Get full text
Journal Article
Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Thaçi, D, Armstrong, A, Lebwohl, M, Blauvelt, A, Paul, C, Puig, L, Wang, M, Vanvoorden, V, Madden, C, Wiegratz, S, Deherder, D, Gordon, KB
Published in Skin (Milwood, N.Y.) (16.11.2022)
Published in Skin (Milwood, N.Y.) (16.11.2022)
Get full text
Journal Article
Bimekizumab Safety in Patients with Moderate to Severe Psoriasis: Analysis of Pooled Data from Phase 2 and 3 Clinical Trials
Reich, K, Blauvelt, A, Lebwohl, M, Papp, KA, Rich, P, Strober, B, De Cuyper, D, Madden, C, Peterson, L, Vanvoorden, V, Warren, RB
Published in Skin (Milwood, N.Y.) (01.01.2021)
Published in Skin (Milwood, N.Y.) (01.01.2021)
Get full text
Journal Article
Bimekizumab Versus Ustekinumab in Plaque Psoriasis: Lasting Efficacy Translates to Rapid and Sustained Improvements in Quality of Life in the BE VIVID Multicenter, Randomized, Double-Blinded Phase 3 Trial
Gordon, K, Foley, P, Rich, P, Duffin, K, Pinter, A, Griffiths, CEM, Wang, M, Vanvoorden, V, Staelens, F, Ciaravino, V, Merola, JF
Published in Skin (Milwood, N.Y.) (01.01.2021)
Published in Skin (Milwood, N.Y.) (01.01.2021)
Get full text
Journal Article
Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE READY, a 56-Week Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study with Randomized Withdrawal
Gordon, K, Foley, P, Krueger, JG, Pinter, A, Reich, K, Vender, R, Vanvoorden, V, Madden, C, Peterson, L, Blauvelt, A
Published in Skin (Milwood, N.Y.) (27.10.2020)
Published in Skin (Milwood, N.Y.) (27.10.2020)
Get full text
Journal Article
Efficacy and Safety of Bimekizumab in Patients with Moderate to Severe Plaque Psoriasis: Results from BE VIVID, a 52-Week Phase 3, Randomized, Double-Blinded, Ustekinumab- and Placebo-Controlled Study
Reich, K, Papp, K, Blauvelt, A, Langley, R, Armstrong, A, Warren, RB, Gordon, K, Merola, JF, Madden, C, Wang, M, Vanvoorden, V, Lebwohl, M
Published in Skin (Milwood, N.Y.) (27.10.2020)
Published in Skin (Milwood, N.Y.) (27.10.2020)
Get full text
Journal Article
Bimekizumab Efficacy and Safety versus Adalimumab in Patients with Moderate to Severe Plaque Psoriasis: Results from a Multicenter, Randomized, Double-Blinded Active Comparator-Controlled Phase 3 Trial (BE SURE)
Warren, RB, Blauvelt, A, Bagel, J, Papp, KA, Yamauchi, P, Armstrong, A, Langley, R, Vanvoorden, V, De Cuyper, D, Peterson, L, Cross, N, Reich, K
Published in Skin (Milwood, N.Y.) (01.01.2021)
Published in Skin (Milwood, N.Y.) (01.01.2021)
Get full text
Journal Article
Efficacité et tolérance du bimékizumab chez des patients présentant un psoriasis en plaques modéré à sévère : résultats de BE VIVID, une étude de phase 3 de 52 semaines, randomisée, en double aveugle, contrôlée versus ustékinumab et versus placebo
Reich, K., Papp, K.A., Blauvelt, A., Langley, R., Armstrong, A., Warren, R.B., Gordon, K., Merola, J.F., Livideanu, C.B., Madden, C., Wang, M., Vanvoorden, V., Lebwohl, M., Medical, C.
Published in Annales de dermatologie et de vénéréologie (01.12.2020)
Published in Annales de dermatologie et de vénéréologie (01.12.2020)
Get full text
Journal Article
59 Health related quality of life (HRQOL) in randomised controlled trials for non small-cell lung cancer (NSCLC) patients — what is the added clinical value
Bottomley, A., Efficace, F., Thomas, R., Vanvoorden, V., Ahmedzai, S.H.
Published in European journal of cancer supplements (01.09.2003)
Published in European journal of cancer supplements (01.09.2003)
Get full text
Journal Article
910 The level of reporting of health-related quality of life in cancer research. Evidence from 123 randomised controlled trials enrolling 36220 cancer patients
Efficace, F., Bottomley, A., Vanvoorden, V., Velikova, G., Greimel, E., van Andel, G.
Published in European journal of cancer supplements (01.09.2003)
Published in European journal of cancer supplements (01.09.2003)
Get full text
Journal Article